Literature DB >> 6139728

Increased muscarinic cholinergic receptors in prefrontal cortices of medicated schizophrenics.

S Watanabe, T Nishikawa, M Takashima, M Toru.   

Abstract

Alterations in 3H-quinuclidinyl benzilate binding sites associated with muscarinic cholinergic receptors were investigated in orbito-frontal and medial frontal cortices from 12 schizophrenics, 6 on-drug and 6 off-drug cases, and from 10 controls. Significantly lower affinities of the sites were found in both areas of schizophrenics than controls. An increase in receptor number was shown only in the orbito-frontal cortex from schizophrenics. On-drug group of schizophrenics did, however, show a significant increase in receptor number and a significant decrease in affinity in both areas, while there were no significant differences in any binding parameters of off-drug schizophrenics from controls. Also in the caudate the similar results were obtained. It is, thus, concluded that alterations in muscarinic cholinergic receptors of schizophrenic patients result from long-term medication with antimuscarinic actions.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6139728     DOI: 10.1016/0024-3205(83)90290-4

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  10 in total

1.  Decreased M1 muscarinic receptor density in rat amphetamine model of schizophrenia is normalized by clozapine, but not haloperidol.

Authors:  Adi Malkoff; Abraham Weizman; Illana Gozes; Moshe Rehavi
Journal:  J Neural Transm (Vienna)       Date:  2008-09-20       Impact factor: 3.575

2.  Changes in BQCA Allosteric Modulation of [(3)H]NMS Binding to Human Cortex within Schizophrenia and by Divalent Cations.

Authors:  Brian Dean; Shaun Hopper; P Jeffrey Conn; Elizabeth Scarr
Journal:  Neuropsychopharmacology       Date:  2015-10-29       Impact factor: 7.853

3.  Neuropathological changes in the nucleus basalis in schizophrenia.

Authors:  M R Williams; R Marsh; C D Macdonald; J Jain; R K B Pearce; S R Hirsch; O Ansorge; S M Gentleman; M Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-12-11       Impact factor: 5.270

Review 4.  Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists.

Authors:  Joseph I Friedman
Journal:  Psychopharmacology (Berl)       Date:  2004-02-19       Impact factor: 4.530

5.  Human electrophysiological correlates of learned irrelevance: effects of the muscarinic M1 antagonist biperiden.

Authors:  Inge Klinkenberg; Arjan Blokland; Wim Riedel; Anke Sambeth
Journal:  Int J Neuropsychopharmacol       Date:  2011-11-18       Impact factor: 5.176

6.  Deletion of PLCB1 gene in schizophrenia-affected patients.

Authors:  Vincenza Rita Lo Vasco; Giuseppina Cardinale; Patrizia Polonia
Journal:  J Cell Mol Med       Date:  2012-04       Impact factor: 5.310

7.  High-Frequency Neuronal Oscillatory Abnormalities in the Phospholipase C-β1 Knockout Mouse Model of Schizophrenia.

Authors:  Matthew R Hudson; Anthony J Hannan; Terence J O'Brien; Nigel C Jones
Journal:  Int J Neuropsychopharmacol       Date:  2019-03-01       Impact factor: 5.176

Review 8.  Molecular targets for treating cognitive dysfunction in schizophrenia.

Authors:  John A Gray; Bryan L Roth
Journal:  Schizophr Bull       Date:  2007-07-07       Impact factor: 7.348

9.  Role of the central cholinergic system in the therapeutics of schizophrenia.

Authors:  Alvin V Terry
Journal:  Curr Neuropharmacol       Date:  2008-09       Impact factor: 7.363

Review 10.  Phospholipase C-β1 Hypofunction in the Pathogenesis of Schizophrenia.

Authors:  Seong-Wook Kim; Taesup Cho; Sukchan Lee
Journal:  Front Psychiatry       Date:  2015-11-17       Impact factor: 4.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.